Table 2 Bivariate and multivariate analysis for the association between demographic and clinical characteristics and multi-refractoriness
From: Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis
VARIABLE | Bivariate, OR (95%CI) | Multivariate, OR (95%CI) |
|---|---|---|
Age at diagnosis | 0.99 (0.96–1.0) | – |
Sex (Female vs male) | 1.67 (0.58–4.73) | 5.94 (0.92–38.20) |
Age at cDMARD treatment | 0.98 (0.95–1.01) | – |
Age at bDMARD treatment | 0.97 (0.93–1.00) | 0.95 (0.90–0.99) |
Time between diagnosis and bDMARD treatment | 0.94 (0.89–1.00) | – |
BMI (kg/m2) | 1.01 (0.94–1.09) | – |
Comorbidities | 1.05 (0.71–1.55) | – |
Erosions (ref yes) | 4.07 (1.79–9.26) | 3.26 (1.18–9.00) |
Extra-articular manifestations (ref yes) | 2.81 (1.0–7.52) | 2.14 (0.59–7.78) |
RF (ref positive) | 0.63 (0.19–2.04) | – |
ACPA (ref positive) | 0.67 (0.24–1.87) | – |
Concurrent metothrexate (ref yes) | 1.83 (0.66–5.10) | – |
Previous cDMARDs | 3.54 (2.05–6.1) | – |
ESR (mm/h) | 1.01 (0.99–1.03) | – |
CRP (mg/dl) | 1.02 (0.99–1.05) | – |
Tender joint count | 1.08 (1.02–1.14) | – |
Swollen count joint | 1.11 (1.02–1.21) | – |
DAS-28 baseline | 1.77 (1.2–2.6) | 2.29 (1.39–3.76) |
DAS-28 at 6 month | 2.29 (1.59–3.29) | – |
ΔDAS-28 (ref < 1.2) | 0.22 (0.09–0.52) | 11.12 (3.34–26.82) |
HAQ | 1.13 (1.03–1.23) | 1.09 (0.92–1.29) |
Smoking status (ref never smokers) | 1.18 (0.54–2.55) | – |